on IL-3 and IL-5-induced eosinophil differentiation from human cord blood mononuclear cells. Clin Exp Immunol 99:124, 1995

6. Iwamoto I, Nakajima H, Endo H, Yoshida S: Interferon- $\gamma$  regulates antigen-induced eosinophil recruitement into the mouse

airways by inhibiting the infiltration of CD4+ T cells. J Exp Med 177:573, 1993

7. Cogan E, Schandené L, Crusiaux A, Cochaux P, Velu T, Goldman M: Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 330:535, 1994

# In Vitro Hypersensitivity to Oxygen of Fanconi Anemia (FA) Cells Is Linked to Ex Vivo Evidence for Oxidative Stress in FA Homozygotes and Heterozygotes

#### To the Editor:

The report by Whitney et al<sup>1</sup> provides a brief mention of a phenotypic feature of Fanconi anemia (FA) cells related to oxygen hypersensitivity. However, one<sup>2</sup> of the two citations used may lead the reader to overlook the in vivo relevance of this phenomenon, as the investigators attributed a "secondary" role for oxygen sensitivity in FA cells. A previous report by Liu et al<sup>3</sup> devoted a section to the abnormalities of oxygen metabolism in FA cells; however, no clear distinction was made between the results of in vitro studies versus the ex vivo data as reported by Korkina et al.<sup>4</sup> Therefore, it is worthwhile to consider the subject of oxidative stress in FA with a reappraisal of the consistency between in vitro and ex vivo evidence.

An involvement of oxidative stress in FA has been long suspected, starting from the pioneering study by Nordenson,<sup>5</sup> who reported an improvement of chromosomal instability following addition of catalase or Cu,Zn superoxide dismutase (Cu,ZnSOD) to cell cultures. Further studies pointed to analogous results by exposing FA cells to low-molecular-weight antioxidants or to a decreased oxygen level.<sup>6-9</sup> Schindler and Hoehn<sup>10</sup> showed a G<sub>2</sub> cell-cycle delay in FA cells, which was counteracted by culturing cells in 5% O<sub>2</sub>, and a recent report from the same group suggested a major role for free iron, and not for superoxide- or H2O2-forming systems in inducing G2 arrest in FA cells.<sup>11</sup> Overall, the information available from in vitro studies suggested excess O2 (Fe?) sensitivity of FA cells, although some studies led to controversial conclusions, eg, reporting the lack of oxygen effect following viral transfection<sup>2</sup> or on FAC gene expression.12 However, these data may have been biased by virus-induced cell immortalization.12

A series of ex vivo studies provided evidence that an abnormality in O<sub>2</sub> metabolism is not merely a cell culture artifact. Rumyantsev et al<sup>13</sup> first reported that freshly drawn white blood cells (WBCs) from FA patients and from their parents produced excess reactive oxygen species (ROS) as detected by luminol-dependent chemiluminescence (LDCL). These data were confirmed on an extended set of Italian FA families,<sup>4</sup> mostly belonging to the FA(A) group.<sup>14</sup> Subsequent studies corroborated those early reports:

(1) Circulating WBCs from FA(A) patients displayed excess levels of the oxidative DNA damage, 8-hydroxy-2'-deoxyguanosine (8OHdG), correlated with LDCL activity as well as with chromosomal instability.<sup>15</sup> These data were consistent with the observation of excess 8OHdG formation in FA(A) cell lines submitted to  $H_2O_2$ stress.<sup>16</sup> Thus, both ex vivo and in vitro evidence pointed to a direct link between ROS formation, oxidative DNA damage, and chromosomal breakages in FA.

(2) Clastogenic factor (CF) was detected in plasma from FA(A) patients, and their siblings and parents.<sup>17</sup> CF was obtained by plasma ultrafiltration, increasing the frequencies of chromosomal breakages in cells from healthy donors. The loss of clastogenic activity by SOD or low-molecular-weight scavengers suggested that plasma CF in FA homozygotes and heterozygotes could be related to the occurrence of in vivo oxidative stress.

(3) Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) was found to be significantly increased in FA patients versus control plasma.<sup>18</sup> Because TNF- $\alpha$  is a recognized effector of ROS release from phagocytes, its elevated levels may be associated with phagocyte activation. Which relationship, if any, exists between TNF- $\alpha$  and CF is a question deserving further investigation. However, the present data suggest that FA patients have a "prooxidant plasma," possibly arising from activated phagocytes.

Lastly, the observation of erythrophagocytosis in bone marrow from early stage FA patients<sup>19</sup> can be viewed as an in vivo condition consistent with a chronic activation of phagocytes.

One limitation in the above data is that studies have been conducted so far either on FA(A) cells<sup>4,14-16</sup> or plasma,<sup>17</sup> or on cells with unknown FA gene defects.<sup>13,18,19</sup> Therefore, further ex vivo studies are required to ascertain any differences in oxidative activity as related to the other FA subtypes.

Notwithstanding the above limitation, the available evidence points to oxidative stress as a major phenotypic hallmark in FA that cannot be overlooked in FA clinical history. The major role for neutrophils in ROS formation, their enhanced depletion in FA progression, as well as the multiple cellular interactions of neutrophils (with, eg, platelets, endothelium, and chondrocytes), altogether make the neutrophil a prime candidate as the affected cell in FA. Ongoing investigations on the roles for FA neutrophils are expected to provide relevant information on the pathogenesis of this disorder.

> Giovanni Pagano Italian National Cancer Institute G. Pascale Foundation Naples, Italy Ludmila G. Korkina Russian Institute of Pediatric Hematology Moscow, Russia Paolo Degan IST Genoa, Italy Domenico Del Principe 2nd Rome University Medical School Rome, Italy Barbara Lindau-Shepard Department of Veterans Affairs Samuel S. Stratton Medical Center Albany, NY Adriana Zatterale Cytogenetics Unit, Elena D'Aosta Hospital Naples, Italy Claudio Franceschi Institute of General Pathology University of Modena Medical School Modena. Italv

## REFERENCES

1. Whitney MA, Royle G, Low MJ, Kelly MA, Axthelm MK, Reifsteck C, Olson S, Braun RE, Heinrich MC, Rathbun RK, Bagby

GC, Grompe M: Germ cell defects and hematopoietic sensitivity to  $\gamma$ -interferon in mice with a targeted disruption of the Fanconi anemia C gene. Blood 88:49, 1996

2. Saito H, Hammond AT, Moses RE: Hypersensitivity to oxygen is a uniform and secondary defect in Fanconi anemia cells. Mutat Res 294:255, 1993

3. Liu JM, Buchwald M, Walsh CE, Young NS: Fanconi anemia and novel strategies for therapy. Blood 84:3995, 1994

4. Korkina LG, Samochatova EV, Maschan AA, Suslova TB, Cheremisina ZP, Afanas'ev IB: Release of active oxygen radicals by leukocytes of Fanconi's anemia patients. J Leukoc Biol 52:357, 1992

5. Nordenson I: Effect of superoxide dismutase and catalase on spontaneously occurring chromosome breaks in patients with Fanconi's anemia. Hereditas 86:147, 1977

6. Raj AS, Heddle JA: The effect of superoxide dismutase, catalase and L-cysteine on spontaneous and on mitomycin C induced chromosomal breakage in Fanconi's anemia and normal fibroblasts as measured by the micronucleus method. Mutat Res 78:59, 1980

7. Joenje H, Arwert F, Eriksson AW, de Koning H, Oostra: AB Oxygen-dependence of chromosomal aberrations in Fanconi's anaemia. Nature 290:142, 1981

8. Dallapiccola B, Porfirio B, Mokini V, Alimena G, Isacchi G, Gandini E: Effect of oxidants and antioxidants on chromosomal breakage in Fanconi's anemia lymphocytes. Hum Genet 69:62, 1985

9. Joenje H, Gille JJP: Oxygen metabolism and chromosomal breakage in Fanconi's anemia, in Schroeder-Kurt TM, Auerbach AD, Obe G (eds): Fanconi Anemia: Clinical, Cytogenetic and Experimental Aspects, Berlin, Germany, Springer, 1989, p 174

10. Schindler D, Hoehn H: Fanconi anemia mutation causes cellular susceptibility to ambient oxygen. Am J Hum Genet 43:429, 1988 11. Poot M, Gross O, Epe B, Pflaum M, Hoehn H: Cell cycle defect in connection with oxygen and iron sensitivity in Fanconi anemia lymphoblastoid cells. Exp Cell Res 222:262, 1996

12. Joenje H, Youssoufian H, Kruyt FAE, dos Santos C, Wevrick R, Buchwald M: Expression of the Fanconi anemia gene *FAC* in human cell lines: Lack of effect of oxygen tension. Blood Cells Mol Dis 21:182, 1995

13. Rumyantsev AG, Samochatova EV, Afanas'ev IB, Korkina LG, Suslova TB, Cheremisina ZP, Maschan AA, Durnev AD, Lurye BL: The role of free oxygen radicals in the pathogenesis of Fanconi's anemia (in Russian). Ter Arkh 61:32, 1989

14. Savoia A, Zatterale A, Del Principe D, Joenje H: Fanconi anaemia in Italy: High prevalence of complementation group A in two geographic clusters. Hum Genet 97:599, 1996

15. Degan P, Bonassi S, De Caterina M, Korkina LG, Pinto L, Scopacasa F, Zatterale A, Calzone R, Pagano G: In vivo accumulation of 8-hydroxy-2-deoxyguanosine in DNA correlates with release of reactive oxygen species in Fanconi's anaemia families. Carcinogenesis 16:735, 1995

16. Takeuchi T, Morimoto K: Increased formation of 8-hydroxydeoxyguanosine, an oxidative DNA damage, in lymphoblasts from Fanconi's anemia patients due to possible catalase deficiency. Carcinogenesis 14:1115, 1993

17. Emerit I, Levy A, Pagano G, Pinto L, Calzone R, Zatterale A: Transferable clastogenic activity in plasma from patients with FA. Hum Genet 96:14, 1995

18. Schulz JC, Shahidi NT: Tumor necrosis factor- $\alpha$  overproduction in Fanconi's anemia. Am J Hematol 42:196, 1993

19. Gordon-Smith EC, Rutherford TR: Fanconi anemia: Constitutional aplastic anemia. Semin Hematol 28:104, 1991

### Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura

#### To the Editor:

Although it has been accepted for decades that most cases of idiopathic thrombocytopenic purpura (ITP) are caused by autoantibodies against platelets,<sup>1</sup> the clinical utility of serologic testing in ITP never has been established.<sup>2</sup> A recent report by Brighton et al<sup>3</sup> analyzed predictive characteristics of direct and indirect tests for platelet-associated IgG (PAIgG) and an antigen capture test (MAIPA) designed to detect autoantibodies specific for platelet gly-coproteins IIb/IIIa or Ib/IX. It was concluded that the MAIPA was better than tests for PAIgG in discriminating immune from nonimmune thrombocytopenia.<sup>3</sup>

We recently analyzed the clinical utility in ITP of a commercially available serologic test for PAIgG, the Capture-P (Immucor, Inc, Norcross, GA). This is a solid-phase red blood cell adherence assay that is used to detect alloantibodies for platelet crossmatching and also has been reported to have high sensitivity and specificity in ITP.<sup>4</sup> In this test, microtiter wells are coated with an agent that binds platelets from autologous (direct method) or allogeneic (indirect method) platelet-rich plasma. Adherent platelets create a substrate for capture of antiplatelet IgG from test plasma. Platelet-bound IgG is detected by subsequent adherence of indicator red blood cells coated with anti-human IgG.

A search of the University of Iowa Hospitals' medical record department computer data base retrieved 359 records that contained results of Capture-P tests performed between August 1989 and July 1994. Of these, 94 records that contained ICD-9 coded primary diagnoses of primary thrombocytopenia (287.3) or thrombocyto-

penia, unspecified (287.5), were reviewed. Patients were retrospectively classified into three groups: (1) ITP (platelet count <150,000/ $\mu$ L, normal or increased numbers of bone marrow megakaryocytes, and no other known cause of thrombocytopenia) (n = 46); (2) thrombocytopenia of other established cause (n = 15); or (3) thrombocytopenia of undetermined cause (incomplete data or criteria for ITP not met, and no other cause of thrombocytopenia established) (n = 33). Group 3 was excluded from analysis.

The sensitivity and specificity of the Capture-P for the clinical diagnosis of ITP were 37% and 67% for the direct method, and 43%

Table 1. Predictive Characteristics of Serologic Tests for Platelet Autoantibodies

Test	Method	Sensitivity	Specificity	Likelihood Ratio*
Capture-P	Direct	17/46 (37%)	10/15 (67%)	1.1
Capture-P	Indirect	20/46 (43%)	9/15 (60%)	1.1
CELIA†	Direct	60/81 (74%)	12/46 (26%)	1.0
ELISA‡	Indirect	30/88 (34%)	41/53 (77%)	1.5
MAIPA§	Modified	33/71 (47%)	34/40 (85%)	3.1

\* Likelihood ratio = sensitivity/(1 - specificity).

 $\dagger$  Competitive enzyme-linked immunoassay for PAlgG (data from Brighton et al  $^{3}$ ).

<sup>‡</sup> Enzyme-linked immunosorbant assay for PAIgG (data from Brighton et al<sup>3</sup>).

§ Modified monoclonal antibody immobilization of platelet antigens (data from Brighton et al<sup>3</sup>).